- Making HSAs more accessible for gig workers.
- Key to Trump’s goal of 3% growth: deregulation.
- How good are randomized control trial studies?
- Thirteen reanalyses (35%) led to interpretations different from that of the original article, 3 (8%) showing that different patients should be treated; 1 (3%), that fewer patients should be treated; and 9 (24%), that more patients should be treated.
- Biden proposes to cover weight loss drugs. Ten-year cost: $25 billion for Medicare and $11 billion for Medicaid.
- Health policy opportunities for Trump.
Category: Drug Prices & Regulations
Thursday Links
- The extraordinary success of vaccines.
- Who should pay for really expensive drugs?
- Trump-era efforts to accelerate vaccine development (Operation Warp Speed) should focus on a new target: bird flu.
- Why do doctors win most of the arbitrations created by the No Surprise (Billing) Act? Because they have better arguments.
Wednesday Links
- Mitch Daniels on a Harris poll: Three fourths of adults over the age of 50 were worried that Social Security would run out in their lifetime, One in five adults over 50 say they have no source of retirement income in addition to Social Security, and only 31 percent have a pension in addition to Social Security 10 years ago.
- Azar: Trump may be tougher than Biden on Medicare drug price negotiations. (InsideHealth Policy)
- Our fiscal problem: Social Security spending is projected to grow at 5.5 percent and Medicare spending at 7.0 percent versus the economy at 2.0 percent and revenue at 4.0 percent.
Expanding Access to Drugs Via Over the Counter
Most care is self-care, at least initially. The most common way Americans care for themselves is with an OTC drug.